ILMN
HealthcareIllumina, Inc. · Medical - Diagnostics & Research · $22B
What is Illumina, Inc.?
Illumina is a San Diego-based life sciences company that develops sequencing and array-based tools for genetic and genomic analysis, serving research, clinical, and commercial markets worldwide.
Illumina generates revenue by selling sequencing instruments, consumables, and related services to genomic research centers, academic institutions, hospitals, and pharmaceutical companies. It also offers genotyping services, instrument service contracts, and cancer detection testing, distributing products directly and through life-science distributors across North America, Europe, and the Asia-Pacific region.
The company was incorporated in 1998 and is headquartered in San Diego, California.
- DNA sequencing instruments and consumables
- Array-based genotyping solutions
- Cancer detection testing services
- Instrument service contracts and licensing agreements
Is ILMN a Good Stock to Buy?
UQS Score rates ILMN as Good overall.
Illumina's Quality and Risk pillars both register as Good, reflecting a business with meaningful operational discipline and a manageable risk profile relative to healthcare peers.
The Growth pillar is rated Weak, signaling that near-term expansion has been challenged, while Moat and Valuation both sit at Neutral.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ILMN pay dividends?
No — Illumina, Inc. does not currently pay a dividend.
Illumina does not currently pay a dividend. As a capital-intensive life sciences company, it has historically directed resources toward research, product development, and expanding its genomics platform rather than returning cash to shareholders through distributions.
When does ILMN report earnings?
Illumina reports earnings on a quarterly cadence, typical for US-listed equities.
Growth has faced headwinds in recent periods, consistent with the Weak Growth pillar rating. The company continues to navigate a shifting demand environment across its research and clinical customer base.
For the most recent quarter's results, see Illumina's investor relations page at investor.illumina.com.
ILMN Price History
-66.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Illumina, Inc.?
Based on Illumina, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Illumina do?
Illumina develops sequencing and array-based solutions for genetic and genomic analysis. Its instruments and consumables are used by research institutions, hospitals, and biotech companies to study DNA for applications ranging from oncology to reproductive health and agriculture.
Does ILMN pay dividends?
No, Illumina does not pay a dividend. The company reinvests capital into its genomics platform and product development rather than distributing cash to shareholders.
When does ILMN report earnings?
Illumina reports on a standard quarterly schedule. For confirmed dates and the latest results, visit the company's investor relations page directly, as specific dates are subject to change.
Is ILMN a good stock to buy?
UQS Score rates ILMN as Good overall, with Quality and Risk pillars both rated Good. However, the Growth pillar is rated Weak, which is a meaningful consideration. The full pillar breakdown is available to Pro members.
Is ILMN overvalued?
Illumina's Valuation pillar is rated Neutral, suggesting the market is pricing the stock in line with a balanced view of its fundamentals. Pro members can access the detailed valuation metrics behind this rating.
How does ILMN compare to its competitors?
Illumina operates alongside companies such as Exact Sciences (EXAS), Quest Diagnostics (DGX), and Waters Corporation (WAT). Each takes a different approach to diagnostics and life-science tools. UQS Score comparisons across these peers are available on their individual pages.
What is ILMN's market cap bracket?
Illumina is classified as a large-cap company, placing it among the more established names in the healthcare and life sciences sector.
Is ILMN a long-term quality indicator?
From a quality standpoint, ILMN scores Good on the Quality pillar, which reflects operational discipline. The Weak Growth rating, however, is a factor long-term investors should weigh. The complete multi-pillar view is available to Pro members.
Unlock Full ILMN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare ILMN side-by-side with genomics and diagnostics peers
- ✓Get the complete analyst view available only to Pro members
Pro Analysis
ILMN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 55.0 | 80.1 | 56.0 | 35.9 | 58.7 | 33.6 | -0.2 |
| May 21, 2026 | 55.2 | 80.2 | 56.0 | 35.9 | 58.7 | 34.3 | -0.7 |
| May 7, 2026 | 55.9 | 78.2 | 56.0 | 35.3 | 60.1 | 42.1 | -0.7 |
| May 4, 2026 | 56.6 | 78.2 | 56.0 | 35.3 | 60.1 | 46.1 | +0.1 |
| May 3, 2026 | 56.5 | 78.2 | 56.0 | 35.2 | 60.1 | 45.8 | -0.4 |
| May 2, 2026 | 56.9 | 78.2 | 56.0 | 35.2 | 60.1 | 48.9 | +0.8 |
| Apr 26, 2026 | 56.1 | 78.2 | 56.0 | 34.0 | 60.1 | 45.1 | +0.3 |
| Apr 19, 2026 | 55.8 | 78.2 | 56.0 | 34.0 | 60.1 | 42.9 | -0.5 |
| Apr 18, 2026 | 56.3 | 78.4 | 56.0 | 34.0 | 60.1 | 45.8 | +0.6 |
| Apr 15, 2026 | 55.7 | 78.5 | 56.0 | 34.0 | 60.1 | 41.8 | -0.1 |
ILMN — Pillar Breakdown
Quality
— 80.1/100 (25%)Illumina, Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 35.9/100 (20%)Illumina, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 58.7/100 (15%)Illumina, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 33.6/100 (15%)Illumina, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 56/100 (25%)Illumina, Inc. has meaningful competitive advantages that should protect its market position. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ILMN.
Score Composition
Financial Data
More Stock Analysis
How is the ILMN UQS Score Calculated?
The UQS (Unified Quality Score) for Illumina, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Illumina, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Illumina, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.